QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newland, A. M Articles by Black, C. D Search for Related Content PubMed PubMed Citation Articles by Newland, A. M Articles by Black, C. D

DRUG INFORMATION ROUNDS

Tumor Progression Associated with Erythropoiesis-Stimulating Agents

Pharmacy Practice Resident, Lahey Clinic Medical Center, Burlington, MA

Curtis D Black, PhD BSPharm

Merck Professor of Clinical Pharmacy, Department of Pharmacy Practice, College of Pharmacy, The University of Toledo, Toledo, OH

Reprints: Dr. Newland, 109B Broadmeadow St., Apt. 7, Marlborough, MA 01752, ashley.newland{at}gmail.com

OBJECTIVE: To evaluate, characterize, compare, and critique trials reporting increased tumor progression in patients with cancer who are receiving erythropoiesis-stimulating agents (ESAs) that led to Food and Drug Administration (FDA) actions for black box warnings and labeling changes.

DATA SOURCES: Literature was accessed through MEDLINE (1950-August 2008) and PubMed (1975-August 2008) using the search terms recombinant erythropoietin, darbepoetin, epoetin, anemia, neoplasms, and disease progression. Articles cited in MedWatch alerts, Oncologic Drugs Advisory Committee meeting briefs, and bibliographies from identified articles were also reviewed.

STUDY SELECTION AND DATA EXTRACTION: All studies published in English with data suggesting increased tumor progression or death due to disease progression in patients receiving ESAs were included.

DATA SYNTHESIS: ESAs are approved for treatment of anemia in several different disease states, including chemotherapy-induced anemia. Ten trials investigating off-label use of ESAs in patients with cancer have reported an increased risk of tumor progression and/or treatment-associated death. Two of these trials reported worse overall survival with ESA treatment compared with placebo (28% vs 23% and 21.9% vs 16.4%), while another trial reported shorter time to death with treatment (68 vs 131 days; p = 0.04). Many of these studies had important limitations, including imbalanced groups at baseline and poor design. Moreover, none of these trials was designed to detect a statistically worse outcome with ESAs; thus, absolute conclusions regarding tumor progression cannot be drawn. As a result, better designed trials with safety as the primary outcome are ongoing.

CONCLUSIONS: Additional studies are needed and being undertaken to qualify and quantify the possible risk of tumor progression with use of ESAs. Prudent practice dictates that until results of these trials are available, ESAs should be used in accordance with FDA labeling.

Key Words: anemia, cancer, darbepoetin, erythropoiesis-stimulating agents, erythropoietin, tumor progression

Published Online, November 18, 2008. www.theannals.com, DOI 10.1345/aph.1L231

This article has been cited by other articles:

				J. J.V. McMurray, I. S. Anand, R. Diaz, A. P. Maggioni, C. O'Connor, M. A. Pfeffer, K. R. Polu, S. D. Solomon, Y. Sun, K. Swedberg, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial Eur J Heart Fail, August 1, 2009; 11(8): 795 - 801. [Abstract] [Full Text] [PDF]